Glycans in cancer and inflammation - Potential for therapeutics and diagnostics

Nature Reviews Drug Discovery

Volumn 4, Issue 6, 2005, Pages 477-488

  Dube, Danielle H ^a   Bertozzi, Carolyn R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER VACCINE; CARBOHYDRATE DERIVATIVE; GANGLIOSIDE; GANGLIOSIDE GM1; GCS 100; GD 39; GLYCAN DERIVATIVE; GLYCOCONJUGATE; GLYCOPROTEIN; GLYCOSIDASE; GLYCOSYLTRANSFERASE; KEYHOLE LIMPET HEMOCYANIN; LECTIN; MUCIN 1; OGT 719; PEPTIDE DERIVATIVE; POLYSIALIC ACID; SELECTIN ANTAGONIST; SIALIC ACID DERIVATIVE; SIALYL LEWIS X ANTIGEN; THERATOPE; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER; CANCER CELL; CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CHRONIC INFLAMMATION; CLINICAL TRIAL; DIAGNOSTIC VALUE; DISEASE COURSE; DRUG EFFICACY; GENOMICS; GLYCOBIOLOGY; GLYCOSYLATION; HUMAN; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MASS SPECTROMETRY; MELANOMA; NONHUMAN; OVARY CANCER; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEOMICS; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; INFLAMMATION; NEOPLASMS; POLYSACCHARIDES;

EID: 20844437106     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd1751     Document Type: Review

References (127)

1. Fabbro, D. & Garcia-Echeverria, C. Targeting protein kinases in cancer therapy. Curr. Opin. Drug Disc. Dev. 5, 701-712 (2002).
2. Sliva, D. Signaling pathways responsible for cancer cell invasion as targets for cancer therapy. Curr. Cancer Drug Targ. 4, 327-336 (2004).
3. Palladino, M. A., Bahjat, F. R., Theodorakis, E. A. & Moldawer, L. L. Anti-TNF-alpha therapies: The next generation. Nat. Rev. Drug Disc. 2, 736-746 (2003).
4. Meezan, E., Wu, H. C., Black, P. H. & Robbins, P. W. Comparative studies on carbohydrate-containing membrane components of normal and virus-transformed mouse fibroblasts. Separation of glycoproteins and glycopeptides by sephadex chromatography. Biochemistry 8, 2518-2524 (1969).
5. Turner, G. A. N-Glycosylation of serum-proteins in disease and its investigation using lectins. Clin. Chim. Acta 208, 149-171 (1992).
6. Axford, J. S. Glycosylation and rheumatic disease. Biochim. Biophys. Acta 1455, 219-229 (1999).
7. Mackiewicz, A. & Mackiewicz, K. Glycoforms of serum α1-acid glycoprotein as markers of inflammation and cancer. Glycoconj. J. 12, 241-247 (1995).
8. Gabius, H. J. Biological information transfer beyond the genetic code: the sugar code. Natur Wissenschaften 87, 108-121 (2000).
9. Saussez, S. et al. Quantitative glycohistochemistry defines new prognostic markers for cancers of the oral cavity. Cancer 82, 252-260 (1998).
10. Shriver, Z., Raguram, S. & Sasisekharan, R. Glycomics: a pathway to a class of new and improved therapeutics. Nat. Rev. Drug Disc. 3, 863-873 (2004).
11. Pancino, G. et al. Purification and characterization of a breast-cancer-associated glycoprotein not expressed in normal breast and identified by monoclonal antibody-83d4. Brit. J. Cancer 63, 390-398 (1991).
12. Matsushita, Y., Cleary K. R., Ota, D. M., Hoff, S. D. & Irimura, T. Sialyl-dimeric Lewis-X antigen expressed on mucin-like glycoproteins in colorectal-cancer metastases. Lab. Invest. 63, 780-791 (1990).
13. Dennis, J. W., Laferte, S., Waghorne, C., Breitman, M. L. & Kerbel, R. S. β1-6 branching of asn-linked oligosaccharides is directly associated with metastasis. Science 236, 582-585 (1987).
14. Kim, Y. J. & Varki, A. Perspectives on the significance of altered glycosylation of glycoproteins in cancer. Glycoconj. J. 14, 569-576 (1997).
15. Sell, S. Cancer-associated carbohydrates identified by monoclonal antibodies. Human Path. 21, 1003-1019 (1990).
16. Hakomori, S. & Zhang, Y. Glycosphingolipid antigens and cancer therapy. Chem. Biol. 4, 97-104 (1997).
17. Taylorpapadimitriou, J. & Epenetos, A. A. Exploiting altered glycosylation patterns in cancer- progress and challenges in diagnosis and therapy. Trends Biotech. 12, 227-233 (1994).
18. Gabius, H. J. Tumor lectinology- at the intersection of carbohydrate chemistry, biochemistry, cell biology, and oncology. Angew. Chem. 27, 1267-1276 (1988).
19. Orntoft, T. F. & Vestergaard, E. M. Clinical aspects of altered glycosylation of glycoproteins in cancer. Electrophoresis 20, 362-371 (1999).
20. Hollingsworth, M. A. & Swanson, B. J. Mucins in cancer: Protection and control of the cell surface. Nat. Rev. Cancer 4, 45-60 (2004).
21. Hakomori, S. Traveling for the glycosphingolipid path. Glycoconj. J. 17, 627-647 (2000).
22. Zhang, S. L. et al. Selection of tumor antigens as targets for immune attack using immunohistochemistry. 1. Focus on gangliosides. Int. J. Cancer 73, 42-49 (1997).
23. Zhang, S. L. et al. Selection of tumor antigens as targets for immune attack using immunohistochemistry. 2. Blood group-related antigens. Int. J. Cancer 73, 50-56 (1997).
24. Fukuda, M. Possible roles of tumor-associated carbohydrate antigens. Cancer Res. 56, 2237-44 (1996).
25. Jurianz, K. et al. Complement resistance of tumor cells: Basal and induced mechanisms. Mol. Immunol. 36, 929-939 (1999).
26. Speiser, D. E. et al. Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: Implications for immunotherapy. J. Exp. Med. 186, 645-653 (1997).
27. Danishefsky, S. J. & Allen, J. R. From the laboratory to the clinic: A retrospective on fully synthetic carbohydrate-based anticancer vaccines. Angew. Chem. 39, 836-863 (2000).
28. Livingston, P. O. Approaches to augmenting the immunogenicity of melanoma gangliosides- from whole melanoma-cells to ganglioside-KLH conjugate vaccines. Immunol. Rev. 145, 147-166 (1995).
29. Ragupathi, G. et al. On the power of chemical synthesis: Immunological evaluation of models for multiantigenic carbohydrate-based cancer vaccines. Proc. Nat'l Acad. Sci. U. S. A. 99, 13699-13704 (2002).
30. Gilewski, T et al. Immunization of metastatic breast cancer patients with a fully synthetic globe H conjugate: A phase I trial. Proc. Nat'l Acad. Sci. U. S. A. 98, 3270-3275 (2001).
31. Slovin, S. F. et al. Carbohydrate vaccines in cancer: Immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man. Proc. Nat'l Acad. Sci. U. S. A. 96, 5710-5715 (1999).
32. Chapman, P. B. et al. A phase II trial comparing five dose levels of BEC2 anti-idiotypic monoclonal antibody vaccine that mimics GD3 ganglioside. Vaccine 22, 2904-2909 (2004).
33. Krug, L. M. et al. Vaccination of small cell lung cancer patients with polysialic acid or N-propionylated polysialic acid conjugated to keyhole limpet hemocyanin. Clin. Cancer Res. 10, 916-923 (2004).
34. Ragupathi, G. et al. Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21. Clin. Cancer Res. 9, 5214-5220 (2003).
35. Dove, A. The bittersweet promise of glycobiology. Nat. Biotech. 19, 913-917 (2001).
36. Holmberg, L. & Sandmaier, B. Vaccination with Theratope (STn-KLH) as treatment for breast cancer. Expert Rev. Vaccines 3, 655-663 (2004).
37. Livingston, P. O. The unfulfilled promise of melanoma vaccines. Clin. Cancer Res. 7, 1837-1838 (2001).
38. Slovin, S. F. et al. Fully synthetic carbohydrate-based vaccines in biochemically relapsed prostate cancer: Clinical trial results with α-N-acetylgalactosamine-O-serine/threonine conjugate vaccine. J. Clin. Oncol. 21, 4292-4298 (2003).
39. Liu, T. M., Guo, Z. W., Yang, Q. L., Sad, S. & Jennings, H. J. Biochemical engineering of surface α2,8 polysialic acid for immunotargeting tumor cells. J. Biol. Chem. 275, 32832-32836 (2000).
40. Chefalo, P., Pan, Y. B., Nagy, N., Harding, C. & Guo, Z. W. Preparation and immunological studies of protein conjugates of N-acylneuraminic acids. Glycoconj. J. 20, 407-414 (2003).
41. Pan, Y. B., Chefalo, P., Nagy, N., Harding, C. & Guo, Z. W. Synthesis and immunological properties of N-modified GM3 antigens as therapeutic cancer vaccines. J. Med. Chem. 48, 875-883 (2005).
42. Zou, W. et al. Bioengineering of surface GD3 ganglioside for immunotargeting human melanoma cells. J. Biol. Chem. 279, 25390-25399 (2004).
43. Lemieux, G. A. & Bertozzi, C. R. Modulating cell surface immunoreactivity by metabolic induction of unnatural carbohydrate antigens. Chem. Biol. 8, 265-275 (2001).
44. Galili, U. Autologous tumor vaccines processed to express α-gal epitopes: a practical approach to immunotherapy in cancer. Cancer Immunol. Immunother. 53, 935-945 (2004).
45. Galili, U., Chen, Z. C. & DeGeest, K. Expression of α-gal epitopes on ovarian carcinoma membranes to be used as a novel autologous tumor vaccine. Gynecol. Oncol. 90, 100-108 (2003).
46. Deriy, L., Chen, Z. C., Gao, G. P. & Galili, U. Expression of α-gal epitopes on HeLa cells transduced with adenovirus containing α1,3galactosyltransferase cDNA. Glycobiology 12, 135-144 (2002).
47. Deriy, L., Ogawa, H., Gao, G. P. & Galili, U. In vivo targeting of vaccinating tumor cells to antigen-presenting cells by a gene therapy method with adenovirus containing the α1,3 galactosyltransferase gene. Cancer Gene Ther. (in press).
48. Burchell, J. M., Mungul, A. & Taylor-Papadimitriou, J. O-linked glycosylation in the mammary gland: Changes that occur during malignancy. J. Mamm. Gland Biol. Neopl. 6, 355-364 (2001).
49. Wong, N. K. et al. Characterization of the oligosaccharides associated with the human ovarian tumor marker CA125. J. Biol. Chem. 278, 28619-28634 (2003).
50. Basu, P. S., Majhi, R. & Batabyal, S. K. Lectin and serum-PSA interaction as a screeninng test for prostate cancer. Clin. Biochem. 36, 373-376 (2003).
51. Peracaula, R. et al. Altered glycosylation pattern allows the distinction between prostate-specifc antigen (PSA) from normal and tumor origins. Glycobiology 13, 457-470 (2003).
52. MacDonald, J. S. Carcinoembryonic antigen screening: Pros and cons. Sem. Oncol. 26, 556-560 (1999).
53. Lloyd, K. O., Burchell, J., Kudryashov, V., Yin, B. W. & Taylor-Papadimitriou, J. Comparison of O-linked carbohydrate chains in MUC-1 mucin from normal breast epithelial cell lines and breast carcinoma cell lines. Demonstration of simpler and fewer glycan chains in tumor cells. J. Biol. Chem. 271, 33325-34 (1996).
54. Dalziel, M. et al. The relative activities of the C2GnT1 and ST3Gal-I glycosyltransferases determine O-glycan structure and expression of a tumor-associated epitope on MUC1. J. Biol. Chem. 276, 11007-11015 (2001).
55. Ramanathan, R. K. et al. Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advance pancreatic cancer. Cancer Immunol. Immunother. 54, 254-264 (2005).
56. Karanikas, V. et al. Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein. J. Clin. Invest. 100, 2783-2792 (1997).
57. Xing, P. X. et al. Phase I study of synthetic MUC1 peptides in cancer. Int. J. Oncol. 6, 1283-1289 (1995).
58. Renkonen, J., Paavonen, T. & Renkonen, R. Endothelial and epithelial expression of sialyl Lewis(x) and sialyl Lewis(a) in lesions of breast carcinoma. Int. J. Cancer 74, 296-300 (1997).
59. Miyake, M., Taki, T., Hitomi, S. & Hakomori, S. Correlation of expression of H/Le(Y)/Le(B) antigens with survival in patients with carcinoma of the lung. New Eng. J. Med. 327, 14-18 (1992).
60. Nakamori, S. et al. Increased expression of sialyl Lewis(X) antigen correlates with poor survival in patients with colorectal-carcinoma- clinicopathological and immunohistochemical study. Cancer Res. 53, 3632-3637 (1993).
61. Shimodaira, K. et al. Carcinoma-associated expression of core 2 β1,6-N-acetylglucosaminyltransferase gene in human colorectal cancer: Role of O-glycans in tumor progression. Cancer Res. 57, 5201-5206 (1997).
62. Gorelik, E., Galili, U. & Raz, A. On the role of cell surface carbohydrates and their binding proteins (lectins) in tumor metastasis. Cancer Metast. Rev. 20, 245-277 (2001).
63. Guo, H. B., Lee, I., Kamar, M. & Pierce, M. N-Acetylglucos aminyltransferase V expression levels regulate cadherin-associated homotypic cell-cell adhesion and intracellular signaling pathways. J. Biol. Chem. 278, 52412-52424 (2004).
64. Demetriou, M., Nabi, I. R., Coppolino, M., Dedhar, S. & Dennis, J. W. Reduced contact-inhibition and substratum adhesion in epithelial-cells expressing GlcNAc-transferase-V. J. Cell Biol. 130, 383-392 (1995).
65. Stanley, P. Selection of lectin-resistant mutants of animal-cells. Meth. Enz. 96, 157-184 (1983).
66. Tao, T. W. & Burger, M. M. Non-metastasizing variants selected from metastasizing melanoma cells. Nature 270, 437-438 (1977).
67. Tokuyama, S. et al. Suppression of pulmonary metastasis in murine B16 melanoma cells by transfection of a sialidase cDNA. Int. J. Cancer 73, 410-415 (1997).
68. Granovsky, M. et al. Suppression of tumor growth and metastasis in Mgat5-deficient mice. Nature Med. 6, 306-312 (2000).
69. Tang, D. G. & Honn, K. V. Adhesion molecules and tumor-metastasis- an update. Inv. Metast. 14, 109-122 (1994).
70. McEver, R. P. Selectin-carbohydrate interactions during inflammation and metastasis. Glycoconj. J. 14, 585-591 (1997).
71. Foster, M. M., Brown, J. R., Wang, L. C. & Esko, J. D. A disaccharide precursor of sialyl Lewis X inhibits metastatic potential of tumor cells. Cancer Res. 63, 2775-2781 (2003).
72. Sarkar, A. K., Rostand, K. S., Jain, R. K., Matta, K. L. & Esko, J. D. Fucosylation of disaccharide precursors of sialyl Lewis(X) inhibit selectin-mediated cell adhesion. J. Biol. Chem. 272, 25608-25616 (1997).
73. Brown, J. R., Fuster, M. M., Whisenant, T. & Esko, J. D. Expression patterns of α 2,3-sialyltransferases and α1,3-fucosyltransferases determine the mode of sialyl Lewis X inhibition by disaccharide decoys. J. Biol. Chem. 278, 23352-23359 (2003).
74. Alper, J. Glycobiology- Turning sweet on cancer. Science 301, 159-160 (2003).
75. Borsig, L. et al. Heparin and cancer revisited: Mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc. Nat'l Acad. Sci. U. S. A. 98, 3352-3357 (2001).
76. Borsig, L., Kim, Y. J., Varki, N. & Varki, A. The role of P-selectin and carcinoma mucins in tumor growth and metastasis. Glycobiology 8, 1143-1143 (1998).
77. Kim, Y. J., Borsig, L., Varki, N. M. & Varki, A. P-selectin deficiency attenuates tumor growth and metastasis. Proc. Nat'l Acad. Sci. U. S. A. 95, 9325-9330 (1998).
78. Shirota, K., Kato, Y., Irimura, T., Konda, H. & Sugiyama, Y. Anti-metastatic effect of the sialyl lewis-X analog GSC-150 on the human colon carcinoma derived cell line KM12-HX in the mouse. Biol. Pharm. Bull. 24, 316-319 (2001).
79. Zacharski, L. R. & Ornstein, D. L. Heparin and cancer. Thromb. Haemost. 80, 10-23 (1998).
80. Nitti, D. et al. Final results of a phase III clinical trial on adjuvant intraportal infusion with heparin and 5-fluorouracil (5-FU) in resectable colon cancer. European Journal of Cancer 33, 1209-1215 (1997).
81. Weissleder, R. Scaling down imaging: molecular mapping of cancer in mice. Nat. Rev. Cancer 2, 11-8 (2002).
82. Weissleder, R. & Ntziachristos, V. Shedding light onto live molecular targets. Nat. Med. 9, 123-8 (2003).
83. Gambhir, S. S. Molecular imaging of cancer with positron emission tomography. Nat. Rev. Cancer 2, 683-93 (2002).
84. Sivolapenko, G. et al. Breast cancer imaging with radiolabelled peptide from complementary-determining region of antitumor immunity. Lancet 346 (1995).
85. Moore, A., Medarova, Z., Potthast, A. & Dai, G. P. In vivo targeting of underglycosylated MUC-1 tumor antigen using a multimodal imaging probe. Cancer Research 64, 1821-1827 (2004).
86. Kayser, H. et al. Biosynthesis of a nonphysiological sialic-acid in different rat organs, using N-propanoyl-D-hexosamines as precursors. J. Biol. Chem. 267, 16934-16938 (1992).
87. Prescher, J. P., Dube, D. H. & Bertozzi, C. R. Chemical remodeling of cell surfaces in living animals. Nature 430, 873-877 (2004).
88. Dube, D. H. & Bertozzi, C. R. Metabolic oligosaccharide engineering as a tool for glycobiology. Curr. Opin. Chem. Biol. 7, 616-625 (2003).
89. Keppler, O. T., Horstkorte, R., Pawlita, M., Schmidts, C. & Reutter, W. Biochemical engineering of the N-acyl side chain of sialic acid: biological implications. Glycobiology 11, 11R-18R (2001).
90. Saxon, E. & Bertozzi, C. R. Cell surface engineering by a modified Staudinger reaction. Science 287, 2007-2010 (2000).
91. Lemieux, G. A., Yarema, K. J., Jacobs, C. L. & Bertozzi, C. R. Exploiting differences in sialoside expression for selective targeting of MRI contrast reagents. J. Am. Chem. Soc. 121, 4278-4279 (1999).
92. Vocadlo, D. J., Hang, H. C., Kim, E. J., Hanover, J. A. & Bertozzi, C. R. A chemical approach for identifying O-GlcNAc-modified proteins in cells. Proc. Nat'l Acad. Sci. U. S. A. 100, 9116-9121 (2003).
93. Hang, H. C., Yu, C., Kato, D. L. & Bertozzi, C. R. A metabolic labeling approach toward proteomic analysis of mucin-type O-linked glycosylation. Proc. Nat'l Acad. Sci. U. S. A. 100, 14846-14851 (2003).
94. Kansas, G. S. Selectins and their ligands: Current concepts and controversies. Blood 88, 3259-3287 (1996).
95. Renkonen, J., Tynninen, O., Hayry, P., Paavonen, T. & Renkonen, R. Glycosylation might provide endothelial zip codes for organ-specific leukocyte traffic into inflammatory sites. Am. J. Pathol. 161, 543-550 (2002).
96. Lowe, J. B. Glycan-dependent leukocyte adhesion and recruitment in inflammation. Curr. Opin. Cell Biol. 15, 531-538 (2003).
97. Ley, K. The role of selectins in inflammation and disease. Trends Mol. Med. 9, 263-268 (2003).
98. Crocker, P. R. & Feizi, T. Carbohydrate recognition systems: Functional triads in cell-cell interactions. Curr. Opin. Struct. Biol. 6, 679-691 (1996).
99. Varki, A. Selectin ligands. Proc. Nat'l Acad. Sci. U. S. A. 91, 7390-7397 (1994).
100. Michie, S. A., Streeter, P. R., Bolt, P. A., Butcher, E. C. & Picker, L. J. The human peripheral lymph-node vascular addressin- an inducible endothelial antigen involved in lymphocyte homing. Am. J. Pathol. 143, 1688-1698 (1993).
101. Rosen, S. D. Endothelial ligands for L-selectin: From lymphocyte recirculation to allograft rejection. Am. J. Pathol. 155, 1013-1020 (1999).
102. Kannagi, R. Regulatory roles of carbohydrate ligands for selectins in the homing of lymphocytes. Curr. Opin. Struct. Biol. 12, 599-608 (2002).
103. Zollner, T. M. & Asadullah, K. Selectin and selectin ligand binding: a bittersweet attraction. J. Clin. Invest. 112, 980-983 (2003).
104. Khor, S. P., McCarthy, K., Dupont, M., Murray, K. & Timony, G. Pharmacokinetics, pharmacodynamics, allometry, and dose selection of rPSGL-Ig for phase I trial. J. Pharm. Exper. Ther. 293, 618-624 (2000).
105. Lee, L. V. et al. A potent and highly selective inhibitor of human α1,3-fucosyltransferase via click chemistry. J. Am. Chem. Soc. 125, 9588-9589 (2003).
106. Lin, C. H. et al. Enzymatic synthesis of a sialyl Lewis X dimer from egg yolk as an inhibitor of E-selectin. Bioorg. Med. Chem. 3, 1625-1630 (1995).
107. Dimitroff, C. J., Kupper, T. S. & Sackstein, R. Prevention of leukocyte migration to inflamed skin with a novel fluorosugar modifier of cutaneous lymphocyte-associated antigen. J. Clin. Invest. 112, 1008-1018 (2003).
108. Armstrong, J. I. et al. A library approach to the generation of bisubstrate analoge sulfotransferse inhibitors. Org. Lett. 23, 2657-2660 (2001).
109. Denis, M. C., Mahmood, U., Benoist, C., Mathis, D. & Weissleder, R. Imaging inflammation of the pancreatic islets in type 1 diabetes. Proc. Nat'l Acad. Sci. U. S. A. 101, 12634-12639 (2004).
110. Sibson, N. R. et al. MRI detection of early endothelial activation in brain inflammation. Mag. Reson. Med. 51, 248-252 (2004).
111. Schofield, L., Hewitt, M. C., Evans, K., Siomos, M. A. & Seeberger, P. H. Synthetic GPI as a candidate anti-toxic vaccine in a model of malaria. Nature 418, 785-789 (2002).
112. Verez-Bencomo, V. et al. A synthetic conjugate polysaccharide vaccine against Haemophilus influenzae type b. Science 305, 522-525 (2004).
113. Mandal, M., Dudkin, V. Y., Geng, X. D. & Danishefsky, S. In pursuit of carbohydrate-based HIV vaccines, Part 1: The total synthesis of hybrid-type gp120 fragments. Angew. Chem. 43, 2557-2561 (2004).
114. Gang, X. D., Dudkin, V. Y., Mandal, M. & Danishefsky, S. J. In pursuit of carbohydrate-based HIV vaccines, Part 2: The total synthesis of high-mannose-type gp120 fragments-evaluation of strategies directed to maximal convergence. Angew. Chem. 43, 2562-2565 (2004).
115. Borman, S. Carbohydrate vaccines: novel chemical and enzymatic oligosaccharide synthesis techniques could lead to a new generation of carbohydrate-based vaccine agents. Chem. Eng. News 82, 31-35 (2004).
116. Knutson, K. L. GMK (Progenics Pharmaceuticals). Curr. Opin. Invest. Drugs 3, 159-164 (2002).
117. Ragupathi, G. et al. A fully synthetic globo H carbohydrate vaccine induces a focused humoral response in prostate cancer patients: A proof of principle. Angew. Chem. 38, 563-566 (1999).
118. Krug, L. M. et al. Vaccination of patients with small-cell lung cancer with synthetic fucosyl GM-1 conjugated to keyhole limpet hemocyanin. Clin. Cancer Res. 10, 6094-6100 (2004).
119. Sabbatini, P. J. et al. Immunization of ovarian cancer patients with a synthetic Lewis(Y)-protein conjugate vaccine: A phase 1 trial. Int. J. Cancer 87, 79-85 (2000).
120. Vandintherjanssen, A., Pals, S. T., Scheper, R., Breedveld, F. & Meijer, C. Dendritic cells and high endothelial venules in the rheumatoid synovial-membrane. J. Rhematol. 17, 11-17 (1990).
121. Salmi, M., Granfors, K., Macdermott, R. & Jalkanen, S. Aberrant binding of lamina propria lymphocytes to vascular endothelium in inflammatory bowel diseases. Gastroenterology 106, 596-605 (1994).
122. Salmi, M. & Jalkanen, S. Regulation of L-selectin expression on cultured bone-marrow leukocytes and their precursors. Eur. J. Immunol. 22, 835-843 (1992).
123. Duijvestijn, A. M., Kerkhove, M., Bargatze, R. F. & Butcher, E. C. Lymphoid tissue-specific and inflammation-specific endothelial-cell differentiation defined by monoclonal-antibodies. J. Immunol. 138, 713-719 (1987).
124. Toppila, S., Paavonen, T., Laitinen, A., Laitinen, L. A. & Renkonen, R. Endothelial sulfated sialyl Lewis X glycans, putative L-selectin ligands, are preferentially expressed in bronchial asthma but not in other chronic inflammatory lung diseases. Am. J. Respir. Cell Mol. Biol. 23,492-498 (2000).
125. Hanninen, A. et al. Vascular addressins are induced on islet vessels during insulitis in nonobese diabetic mice and are involved in lymphoid-cell binding to islet endothelium. J. Clin. Invest. 92, 2509-2515 (1993).
126. Turunen, J. P. et al. De-novo expression of endothelial sialyl Lewis(a) and sialyl Lewis(X) during cardiac transplant rejection- superior capacity of a tetravalent sialyl Lewis(X) oligosaccharide in inhibiting L-selectin-dependent lymphocyte adhesion. J. Exp. Med. 182, 1133-1141 (1995).
127. Slovin, S. et al. Multivalency in a phase II prostate cancer (PC) vaccine trial: Are more antigens better? Proc. Am. Soc. Clin. Oncol. 22, 167 (2003).